Article

Abbott completes acquisition of Visiogen

Abbott Laboratories has completed its acquisition of privately held eye-care company Visiogen, adding to its vision-care business an accommodating IOL technology (Synchrony) designed to address presbyopia in patients with cataracts.

Abbott Park, IL

-Abbott Laboratories has completed its acquisition of privately held eye-care company Visiogen, adding to its vision-care business an accommodating IOL technology (Synchrony) designed to address presbyopia in patients with cataracts.

The $400 million cash purchase boosts Abbott’s presence in the vision-care segment, which it entered in February with the acquisition of Advanced Medical Optics, according to a prepared statement from the company.

“Visiogen immediately provides Abbott Medical Optics [AMO] with a talented team of dedicated professionals and an entry point into the accommodating IOL market,” said Jim Mazzo, senior vice president, AMO.

The proprietary accommodating IOL received CE mark designation and has been available commercially in Europe since January. It is under review by the FDA.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
© 2025 MJH Life Sciences

All rights reserved.